BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
Key facts
- Study ID
- NCT04649385
- Run by
- BeiGene
- People needed
- 157
- Starts
- 2021-03-04
- Expected to finish
- 2026-05-15
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Icahn School of Medicine At Mount Sinai — New York, New York, United States
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States
- Ut Health San Antonio Mays Cancer Center — San Antonio, Texas, United States
- Prince of Wales Hospital — Randwick, New South Wales, Australia
- Ashford Cancer Centre Research Northeast — Windsor Gardens, South Australia, Australia
- Peter Maccallum Cancer Centre — Melbourne, Victoria, Australia
- Linear Clinical Research — Nedlands, Western Australia, Australia
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
- Henan Cancer Hospital — Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China
- Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China
- West China Hospital, Sichuan University — Chengdu, Sichuan, China
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality, China
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
- Auckland City Hospital — Auckland, New Zealand
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea
- Samsung Medical Center — GangnamGu, Seoul Teugbyeolsi, South Korea
- The Catholic University of Korea, Seoul St Marys Hospital — SeochoGu, Seoul Teugbyeolsi, South Korea
- Severance Hospital Yonsei University Health System — SeodaemunGu, Seoul Teugbyeolsi, South Korea
- Asan Medical Center — SongpaGu, Seoul Teugbyeolsi, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.